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Abstract
Paired-end sequencing is emerging as a key technique for assessing genome rearrangements and structural variation on a
genome-wide scale. This technique is particularly useful for detecting copy-neutral rearrangements, such as inversions and
translocations, which are common in cancer and can produce novel fusion genes. We address the question of how much
sequencing is required to detect rearrangement breakpoints and to localize them precisely using both theoretical models
and simulation. We derive a formula for the probability that a fusion gene exists in a cancer genome given a collection of
paired-end sequences from this genome. We use this formula to compute fusion gene probabilities in several breast cancer
samples, and we find that we are able to accurately predict fusion genes in these samples with a relatively small number of
fragments of large size. We further demonstrate how the ability to detect fusion genes depends on the distribution of gene
lengths, and we evaluate how different parameters of a sequencing strategy impact breakpoint detection, breakpoint
localization, and fusion gene detection, even in the presence of errors that suggest false rearrangements. These results will
be useful in calibrating future cancer sequencing efforts, particularly large-scale studies of many cancer genomes that are
enabled by next-generation sequencing technologies.
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Introduction
Cancer is a disease driven by selection for somatic mutations.
These mutations range from single nucleotide changes to large-
scale chromosomal aberrations such as deletion, duplications,
inversions and translocations. While many such mutations have
been cataloged in cancer cells via cytogenetics, gene resequencing,
and array-based techniques (i.e. comparative genomic hybridiza-
tion) there is now great interest in using genome sequencing to
provide a comprehensive understanding of mutations in cancer
genomes. The Cancer Genome Atlas (http://cancergenome.nih.
gov/index.asp) is one such sequencing initiative that focuses
sequencing efforts in the pilot phase on point mutations in coding
regions. This approach largely ignores copy neutral genome
rearrangements including translocations and inversions. Such
rearrangements can create novel fusion genes, as observed in
leukemias, lymphomas, and sarcomas [1–3]. The canonical
example of a fusion gene is BCR-ABL, which results from a
characteristic translocation (termed the ‘‘Philadelphia chromo-
some’’) in many patients with chronic myelogenous leukemia
(CML) [3]. The advent of Gleevec, a drug targeted to the BCR-
ABL fusion gene, has proven successful in treatment of CML
patients [4], invigorating the search for other fusion genes that
might provide tumor-specific biomarkers or drug targets.
Until recently, it is was generally believed that recurrent
translocations and their resulting fusion genes occurred only in
hematological disorders and sarcomas, with few suggesting that
such recurrent events were prevalent across all tumor types
including solid tumors [5,6]. This view has been challenged by the
discovery of a fusion between the TMPRSS2 gene and several
members of the ERG protein family in prostate cancer [7] and the
EML4-ALK fusion in lung cancer [8].
These studies raise the question of what other recurrent
rearrangements remain to be discovered. One strategy for
genome-wide high-resolution identification of fusion genes and
other large scale rearrangements is paired-end sequencing of
clones, or other fragments of genomic DNA, from tumor samples.
The resulting end-sequence pairs, or paired reads, are mapped back
to the reference human genome sequence. If the mapped locations
of the ends of a clone are ‘‘invalid’’ (i.e. have abnormal distance or
orientation) then a genomic rearrangement is suggested (See
Figure 1 and Methods). This strategy was initially described in the
End Sequence Profiling approach [9] and later used to assess
genetic structural variation [9,10]. An innovative approach
utilizing SAGE-like sequencing of concatenated short paired-end
tags successfully identified fusion transcripts in cDNA libraries
[11]. Present and forthcoming next-generation DNA sequencers
hold promise for extremely high-throughput sequencing of paired-
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be able to produce millions of paired reads of approximately 30 bp
from fragments of length 500–1000 bp [12], while the SOLiD
system from Applied Biosystems promises 25 bp reads from each
end of size selected DNA fragments of many sizes [13]. Similar
strategies coupling the generation of paired-end tags with 454
sequencing have also been described [14,15].
Whole genome paired-end sequencing approaches allow for a
genome-wide survey of all potential fusion genes and other
rearrangements in a tumor. This approach holds several
advantages over transcript or protein profiling in cancer studies.
First, discovery of fusion genes using mRNA expression [7], cDNA
sequencing, or mass spectrometry [16] depends on the fusion
genes being transcribed under the specific cellular conditions
present in the sample at the time of the assay. These conditions
might be different than those experienced by the cells during
tumor development. Second, measurement of fusions at the DNA
sequence level focuses on gene fusions due to genomic rearrange-
ments and thus is less impeded by splicing artifacts or trans splicing
[17]. Finally, genome sequencing can identify more subtle
regulatory fusions that result when the promoter of one gene is
fused to the coding region of another gene, as in the case with with
the c-Myc oncogene fusion with the immunoglobin gene promoter
in Burkitt’s lymphoma [18].
In this paper, we address a number of theoretical and practical
considerations for assessing cancer genome organization using
paired-end sequencing approaches. We are largely concerned with
detecting a rearrangement breakpoint, where a pair of non-
adjacent coordinates in the reference genome is adjacent (i.e.
fused) in the cancer genome. In particular, we extend this idea of a
breakpoint to examine the ability to detect fusion genes.
Specifically, if a clone with end sequences mapping to distant
locations identifies a rearrangement in the cancer genome, does
this rearrangement lead to formation of a fusion gene? Obviously,
sequencing the clone will answer this question, but this requires
additional effort/cost and may be problematic; e.g. most next-
generation sequencing technologies do not ‘‘archive’’ the genome
in a clone library for later analysis (for the sake of simplicity we will
use the term ‘‘clone’’to refer to any contiguous fragment that is
sequenced from both ends). We derive a formula for the
probability of fusion between a pair of genomic regions (e.g.
genes) given the set of all mapped clones and the empirical
distribution of clone lengths. These probabilities are useful for
prioritizing follow-up experiments to validate fusion genes. In a
test experiment on the MCF7 breast cancer cell-line, 3,201 pairs of
genes were found near clones with aberrantly mapping end-
sequences. However, our analysis revealed only 18 pairs of genes
with a high probability (.0.5) of fusion, of which six were tested
and five experimentally confirmed (Table 1).
The advent of high throughput sequencing strategies raises
important experimental design questions in using these technol-
ogies to understand cancer genome organization. Obviously,
sequencing more clones improves the probability of detecting
fusion genes and breakpoints. However, even with the latest
sequencing technologies, it would be neither practical nor cost
effective to shotgun sequence and assemble the genomes of
thousands of tumor samples. Thus, it is important to maximize the
probability of detecting fusion genes with the least amount of
sequencing. This probability depends on multiple factors including
the number and length of end-sequenced clones, the length of
Figure 1. Schematic of breakpoint calculation. (A) The endpoints
of a clone C from the cancer genome map to locations xC and yC (joined
by an arc) on the reference genome that are inconsistent with C being a
contiguous piece of the reference genome. This configuration indicates
the presence of a breakpoint (a,b) that fuses at f in the cancer genome.
(B) The coordinates (a,b) of the breakpoint are unknown but lie within
the trapezoid described by Equation 1. The observed length of the
clone is given by LC=(a2xC)+(b2yC). The rectangle U6V describes the
breakpoints that lead to a fusion between genes U and V.
doi:10.1371/journal.pcbi.1000051.g001
Author Summary
Cancer is driven by genomic mutations that can range
from single nucleotide changes to chromosomal aberra-
tions that rearrange large pieces of DNA. Often, these
chromosomal aberrations disrupt a gene sequence, and
even fuse the sequences of two genes, producing a
‘‘fusion gene.’’ Fusion genes have been identified as key
participants in the development of several types of cancer.
Using genome-sequencing technology it is now possible
to identify chromosomal aberrations genome-wide and at
high resolution. In this paper, we address the question of
how much sequencing is required to detect a chromo-
somal aberration and to determine the location of the
aberration precisely enough to identify if a fusion gene is
created by this aberration. We derive a mathematical
formula that accurately predicts a number of fusion genes
in a breast cancer sequencing study. We also demonstrate
how the ability to detect chromosomal aberrations and
fusion genes depends on both the size of the fusion gene
and the parameters of the genome sequencing strategy
that is used. These results will be useful in calibrating
future cancer sequencing efforts, especially those using
next-generation sequencing technologies.
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Here, we derive (theoretically and empirically) several formulae
that elucidate the trade-offs in experimental design of both current
and next-generation sequencing technologies. Our probability
calculations and simulations demonstrate that even with current
paired-end technology we can obtain an extremely high
probability of breakpoint detection with a very low number of
reads. For example, more than 90% of all breakpoints can be
detected with paired-end sequencing of less than 100,000 clones
(Table 2). Additionally, next-generation sequencers can potentially
detect rearrangements with a greater than 99% probability and
localize the breakpoints of these rearrangements to intervals of less
than 300 bp in a single run of the machine (Table 2).
Results
Computing the Probability of Fusion Genes
Given a set of clones from a cancer genome, we want to
compute the probability that these clones identify a fusion gene in
the cancer genome, i.e. a fusion of two different genes from the
reference genome. We consider the cancer genome as a
rearranged version of the reference human genome and assume
that there exists a mapping between coordinates of the two
genomes. The reference genome is described by a single interval of
length G; i.e. we concatenate multiple chromosomes into a single
coordinate system. We define a breakpoint (a,b) as a pair of non-
adjacent coordinates a and b in the reference genome that are
adjacent in the cancer genome. Correspondingly, we define the
fusion point as the coordinate f in the cancer genome such that the
point a maps to f and the point b maps to f+1. Note that in the
genome rearrangement literature, a fusion point is also called a
breakpoint [19]. Consider a clone C containing f. If the
breakpoints a and b are far apart (e.g. on different chromosomes)
then the endpoints of C will map to two locations, xC and yC, on the
reference genome that are inconsistent with C being a contiguous
fragment of the reference genome (Figure 1A). In this case, we say
that (xC,yC)i sa ninvalid pair [20]. Observing an invalid pair (xC,yC)
does not identify the breakpoint (a,b) exactly. However, if we know
that the length of the clone C lies within the range [Lmin,Lmax], and
we assume that: (i) only a single breakpoint is contained in a clone;
and (ii) a.xC and b.yC (without loss of generality: See Methods);
then breakpoint (a,b) that are consistent with (xC,yC) must satisfy
Lminƒ a{xC ðÞ z b{yC ðÞ ƒLmax: ð1Þ
If we plot an invalid pair (xC,yC) as a point in the two dimensional
space G6G then the breakpoints (a,b) satisfying the above equation
define a trapezoid (or triangle when Lmin=0) (Figure 1).
If multiple clones contain the same fusion point f, then the
corresponding breakpoint (a,b) lies within the intersection I of the
trapezoids corresponding to the clones. Conversely, we will assume
that if the trapezoids defined by several invalid pairs intersect, then
they share a common breakpoint. We call a set of clones whose
trapezoids have non-empty intersection a cluster. Figure 2 displays
a cluster of six clones from the MCF7 breast cancer cell line. As
the number of clones that are end-sequenced increases, more
clones will contain the same fusion point and more clusters will be
formed. Thus, the area of I will decrease, and therefore the
uncertainty in the location of the fusion point decreases.
Now, each gene in the reference genome defines an interval
U=[s,t] where s is the 59 transcription start site and t is the 39
transcription termination site. Consider two genes with intervals U
Table 1. Fusion probability predictions and sequencing results for clusters in breast cancer.
Start Gene End Gene Fusion Probability Cluster Size Sequencing Supporting Fusion Cell Line/Primary Tumor
ASTN2 PTPRG 1 2 Yes{ MCF7
BCAS4 BCAS3 1 20 Yes{ MCF7
KCND3 PPM1E 0.99 12 Yes MCF7
NTNG1 BCAS1 0.99 6 Yes MCF7
BCAS3 ATXN7 0.83 8 Yes{ MCF7
ZFP64 PHACTR3 0.6322 2 No BT474
CT012_HUMAN UBE2G2 0.0880 1 No Breast
VAPB ZNFN1A3 0.0842* 3 Yes BT474
BMP7 EYA2 0.0324 4 No{ MCF7
KCNH7 TDGF1 0.0215 1 No Breast
SULF2 TBX4 0.00656 2 No MCF7
NACAL NCOA3 0.0057 2 No MCF7
MRPL45 TBC1D3C 0.0005 1 No BT474
U1 NP_060028.2 0.0005 1 No Breast
RBBP9 ITGB2 0.0005 1 No Breast
Y SYNPR ,0.0001 4 No MCF7
PRR11 TMEM49 ,0.0001 9 No MCF7
BMP7 Q96TB ,0.0001 3 No MCF7
The gene order shown indicates ‘‘start’’ and ‘‘end’’ positions with respect to the direction of transcription. Note that VAPB/ZNFNA13 has low probability of fusion, but
there are many pairs of genes with low probability of fusion in this region. The probability that any one of these gene pairs fuse is ..30. All clones in a cluster are non-
redundant (the same clones do not reappear multiple times in a cluster). Additional clones have been sequenced [22], but these did not overlap any predicted fusion
genes – these sequenced clones were also found not to contain fusion genes.
{A single clone contained more than two chromosomal segments, i.e. the clone is not a simple fusion of two genomic loci.
doi:10.1371/journal.pcbi.1000051.t001
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that lies in U6V. This breakpoint is detected if (u,v) lies in I. Thus,
an approximate probability for the existence of a fusion gene is the
fraction of I that lies within the rectangle U6V. We obtain a better
estimate of the probability of fusion by considering the empirical
distribution of clone lengths. The exact probability of the gene
fusion is given by the probability mass that lies within the
intersection of I and the rectangle U6V defined by the pair of
genes. An efficient algorithm for computing these probabilities is
given in Methods.
Fusion Gene Predictions in Breast Cancer
We made predictions of fusion genes for the MCF7, BT474,
and SKBR3 breast cancer cell lines as well as two primary tumors
using data from end sequence profiling of these samples [21,22].
Approximately, 71 Mb of end-sequence was obtained from these 5
samples, ,29 Mb (corresponding to .47 clonal coverage) coming
from the MCF7 cell line. Across all samples, a total of 1,141
invalid pairs were obtained. These formed 919 clusters, 95 of
which contained more than one clone.
We applied our method of computing fusion gene probability to
each of these samples, using the distribution of clone lengths in
each library for these calculations. Figure S1 shows this empirical
distribution for the MCF7 library. Table 1 shows the results of our
predictions for fully sequenced BACs across multiple breast cancer
cell lines and primary tumors, sorted according to fusion
probability. We have successfully validated a number of these
highest ranked predictions by sequencing the entire clone and
identifying the exact location of the breakpoint and point of gene
fusion (See Methods). Sequencing also showed that certain clones
contain multiple rearrangement breakpoints with more than two
contiguous segments of the reference genome present in a single
clone (Table 1). In these cases, we ensure that the breakpoint
associated to each gene in the fusion disrupts the corresponding
gene. Such multiple rearranged regions have been observed to still
form fusion transcripts as in the case of BCAS4/BCAS3 [11,23].
Figure 2 illustrates the computation of fusion probability for one
high-scoring prediction (NTNG1/BCAS1). The strong correspon-
dence between fusion probability prediction and subsequent
validation of the breakpoints by sequencing in Table 1 illustrates
the predicative power of our method. Table 1 also indicates the
power of the technique in predicting clones that do not have fusion
genes. Only one clone with fusion probability below 50%
contained a fusion gene (VAPB/ZNFN1A3). The data suggests a
strong correlation between gene rectangle size (the product of gene
Figure 2. Prediction of a fusion between the NTNG1 and BCAS1
genes. The rectangle indicates the possible locations of a breakpoint
on chromosomes 1 and 20 that would result in a fusion between
NTNG1 and BCAS1. Each trapezoid indicates possible locations for a
breakpoint consistent with an invalid pair. Assuming that all clones
contain the same breakpoint, this breakpoint must lie in the
intersection of the trapezoids (shaded region). Approximately 69% of
this shaded region intersects (darkly shaded region) the fusion gene
rectangle, giving a probability of fusion of approximately 0.69. The
empirical distribution of clone lengths reveals that not all clone lengths
are equally likely (e.g. extremely long or short clones are rare). Using this
additional information, our improved estimate for the probability of
fusion is .0.99.
doi:10.1371/journal.pcbi.1000051.g002
Table 2. Breakpoint detection and localization for different sequencing strategies.
Clone Length(L) Paired Reads (N) Clone Coverage (c) E (|Hf|) Pf E (|Hf*|) Pf*
1k b 4 0 610
6 13.36 295 ..99 289 .99
1k b 1 610
6 .336 972 .15 658 .012
2k b 2 0 610
6 13.36 593 ..99 581 .99
2k b 1 610
6 .666 1889 .28 1296 .044
10 kb 5610
6 16.76 2393 ..99 2378 ..99
10 kb 1610
6 3.36 7342 .81 5657 .50
40 kb 2610
6 26.76 5998 ..99 5997 ..99
40 kb .1610
6 1.336 35587 .49 25124 .14
150 kb .5610
6 256 23997 ..99 76807 .71
150 kb .1610
6 56 93169 .92 72022 .80
150 kb .012610
6 .66 142510 .26 97457 0.037
The probability Pf of detecting a fusion point and the expected length E(|Hf|) of a breakpoint region under various clone lengths (L) and number of end-sequenced
clones (N). The values of N and L are chosen to reflect current or proposed sequencing platforms, with the last value for the 150 kb clones representing our current
status on the MCF7 cell line. Pf* and E(|Hf*|) correspond to the probability for, and expected size of, a breakpoint region in the case when two clones are required to
span f. The small clone lengths (1 kb, 2 kb) and large number of reads represent what one might achieve in a single run with new technologies (under perfect mapping
of end sequences). For a comparison of E(|Hf|) and N for a fixed Pf=.99 over a continuous range of clone lengths, see Figure S6.
doi:10.1371/journal.pcbi.1000051.t002
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have higher fusion probabilities and greater likelihood of being
validated (Figure 3). A similar trend is observed in chimerDB, a
database of fusion genes in cancer derived from mRNA, EST,
literature and database searches [24].
Detection and Localization of Genome Rearrangements
We now consider the problem of how much sequencing is
required to detect a genome rearrangement and to localize the
breakpoint of a rearrangement. Consider an idealized model in
which R clones, each of fixed length L are picked uniformly at
random from a cancer genome of length G (where G will equal the
diploid genome size, ,6610
6 bp) and end-sequenced. These end
sequences are mapped to the reference genome and the fraction f
of clones with uniquely mapped ends yields N=fR clones that can
be used to identify rearrangements. The fraction f of clones
uniquely mapped varies significantly among different sequencing
technologies.In anESPstudy,with paired-end Sanger sequencing of
BACs, 90% of reads were mappable with 58% uniquely mapped
[22]. A recent study that used 454 sequencing to identify structural
variants in the human genome reported 63% mapping of sequences
with recognizable linker sequences, and 41% of all reads mapped
[15]. Note that the 454 reads are of significantly longer (average
109 bp) compared to other next generation sequencing technologies
(average 20–30 bp) [12,13,15] and thus even lower mapping
efficiencies are expected for these shorter reads.
A fusion point, f, on the cancer genome is detected if a uniquely
mapped clone contains it (Figure 4). Using the Clarke-Carbon
formula [25,26] (See Methods), the probability Pf of detection of f
is given by
Pj&1{e{c, ð2Þ
where c=NL/G is the clonal coverage. If only a single clone contains
a fusion point, then the fusion point is localized to within L bp. If
multiple clones contain a fusion point, then the fusion point is
localized moreprecisely. We define the breakpoint region, Hf,a st h e
interval determined by the intersection of all clones that contain f.
Thus, |Hf| defines the localization of f, or the uncertainty in
mappingf.Sincelocalizinga fusion point to withinL,re qu ir e so n lya
single clone containing f,w ef i n d( s e eM e t h o d s )t h a t
Pr Hj jj ~L ðÞ &Le{c 1{e{N
G
  
: ð3Þ
Furthermore, we find that for s,L,
Pr Hj jj ~s ðÞ ½  &se{Ns
G 1{e{N
G
   2
: ð4Þ
These equations allow us to estimate the expected length of Hf,
conditioned on f being covered (otherwise, Hf is not defined) as
E Hj jj j j is covered ðÞ &
1{e{N
G
1{e{c
 !
| L2e{cz
X L{1
s~1
s2e{Ns
G 1{e{N
G
  
 !
:
ð5Þ
See Methods section for full derivation and closed form solution
(Equation 24). We evaluated the error in this approximation by
simulation (See Text S1 for descriptions of all simulations). Figure
S2 shows that Equation 5 very closely models the average
observed |Hf|. The relative error between the average observed
length of the breakpoint region and Equation 5 was 0.02.
We also assessed the effect of different clone lengths, L, and
number of clones, N, on the expected length of the breakpoint
Figure 3. Fusion genes and gene lengths. (A) Probability of fusion
vs. the product of gene lengths involved in the fusion indicates higher
fusion probabilities for pairs of larger genes. Larger circles indicate gene
pairs experimentally validated by further sequencing. A ‘‘Positive
Result’’ indicates a predicted fusion for which sequencing results
supported a fusion gene. A ‘‘Negative Result’’ indicates a predicted
fusion for which sequencing results did not support a fusion gene. (B)
The number of fusion genes in chimerDB [23] plotted as a function of
the product of gene lengths in the fusion.
doi:10.1371/journal.pcbi.1000051.g003
Figure 4. Schematic of a breakpoint region. A fusion point f on the cancer genome contained in multiple clones. The leftmost and rightmost
clones determine the breakpoint region Hf in which the fusion point can occur.
doi:10.1371/journal.pcbi.1000051.g004
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that as the number of reads, N, increases, the uncertainty in
localization (|Hf|) decreases. Interestingly, note that the 40 kb
clones are most advantageous when localization |Hf|=40 kb is
desired. A similar effect was observed for the 150 kb and 2 kb
clones. Thus, there is a direct correlation between the clone length
and the ability to localize a fusion point to a given sized interval,
implying that the choice of clone lengths impacts the ability to
detect fusions of a specific size.
Comparison of Sequencing Strategies
Formulas 2 and 5 provide a framework for examining a variety
of choices of sequencing parameters L, N, and c. Table 2 and
Figures S3, S4, and S5 demonstrate the effect of using different
clone lengths and varying numbers of paired reads on the ability to
detect and localize a fusion point. Table 2 also indicates the effect
of such parameters on the ability to detect and localize clusters of
invalid pairs, as defined by Formulas 25 and 26. One can see that
a distinct trade-off exists between detection, in which larger clones
hold a distinct advantage, and localization, in which case smaller
clones are advantageous. Longer clones (e.g. BACs of 150 kb) are
more pragmatic for sequencing projects using a smaller number of
paired reads, but the advent of low cost, highly parallel sequencing
of small clones could soon yield extremely high probability of
detection (high Pf) and extremely high resolution of fusion points
(small |Hf|).
Lengths of Fusion Genes
Since our simulations revealed that the choice of sequencing
parameters affects the ability to localize breakpoint regions to
intervals of different lengths (Figure 5), we further explored what
lengths might be advantageous for identification of fusion genes.
There is considerable variation in sizes of human genes (Figure 6).
When considering all known transcripts [27], the median gene size
is approximately 20 kb and the mean is approximately 40 kb.
However, examination of chimerDB shows a clear bias towards
larger genes, with a median gene size of 40 kb and a mean gene
size of 90 kb. It is tempting to speculate on the reasons for this
bias. One possibility is ascertainment bias, as larger fusion genes
would be easier to identify via cytogenetic techniques which to
date have been the technique used to identify most fusion genes.
Additionally, random breakage of the genome would favor fusions
involving larger genes, as the probability of a breakpoint
disrupting a large gene would be greater than for a small gene.
We examined the length distribution of random fusion genes by
simulation. We selected random breakpoints in the genome, and if
a breakpoint formed a fusion gene we recorded the length of the
resulting fusion gene (Figure 6). It is interesting to note that these
random fusion events resulted in much larger genes than observed
in the normal genome or chimerDB (median and mean gene sizes
of 155 kb and 284 kb, respectively). Though further investigations
are needed, one possible explanation is that known fusion genes
have a biased size distribution because they are selected for
functional reasons. We also examined the distribution of
transcription factor genes and kinase genes, both of which are
members of multiple fusion genes (Figure 6). Interestingly, the size
distribution of kinases is closer to the chimerDB distribution, while
the size distribution of transcription factors is closer to the size
distribution of all known genes.
The variation in gene sizes for different classes of genes (Figure 6)
suggests that one consider a wide range of gene sizes when
assessing our ability to detect fusion genes. Figure 7 shows the
number of clones, for different lengths, that are required to achieve
a fusion probability greater than 0.5 for a random gene pair of
fixed size. Note that the breakpoint could exist at any position
within either gene. Smaller clone sizes clearly hold a distinct
advantage in fusion probability for equal clonal coverage while
large clones perform better for a fixed number of paired reads
(Figure 7A). This is not surprising, as a significantly higher number
of paired reads is required to achieve the same coverage with smaller
clones. In particular, 75 times more paired reads from 2 kb clones
are needed to obtain the same clonal coverage as 150 kb clones.
There is also a relationship between the size of a fusion gene and
the probability of detecting the fusion (Figure 7B). Since larger
clones create larger trapezoids (Figure 1) the use of larger clones
increases the probability that the trapezoid defined by the clone
intersects the rectangle defined by the two genes, thus producing a
higher probability of detection of a breakpoint. However, this
effect is counteracted by the fact that larger clones also yield larger
breakpoint regions, leading to lower fusion probabilities since only a
small fraction of a larger trapezoid typically overlaps the gene
rectangle. The optimal clone length for fusion gene identification is
directly related to the length of fusion genes. Thus, the length of
fusion genes that one wants to detect with high probability is an
Figure 5. Probability of localizing a fusion point to an interval of a given length. A fusion point f is localized to length s if the
corresponding breakpoint point region Hf has length s or less. When s exceeds the clone length L, only a single clone is required to achieve this
localization and consequently the probability of localization is the probability that at least one clone contains the fusion point. In the case of 1 M
paired reads the 40 kb and 150 kb curves are nearly indistinguishable. Note that each curve is obtained using a fixed clone length, and that the use of
a distribution of clone lengths would create a less abrupt transition.
doi:10.1371/journal.pcbi.1000051.g005
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example, if a fusion gene is 40 kb in length, the average fusion
probability is significantly greater when using the same number of
40 kb clones compared to 2 kb or 10 kb clones, because of the
greater genomic coverage provided by the larger clones. However,
in this scenario 40 kb clones also perform nearly as well as 150 kb
clones (Figure 7B), because the 40 kb clones have better break-
point localization (Figure 5). If the fusion gene size is increased to
150 kb, then 150 kb clones are superior since the poorer
breakpoint localization has limited effect on prediction of a large
fusion gene. One additional consideration is that larger clones
(e.g.150 kb) consistently show lower variance in fusion probabil-
ities (Figure S7) due to their higher probability of detecting a
fusion. This makes larger clones more reliable when performing
studies across multiple tumor samples, especially when the number
of paired reads available for its sample is limited.
Effects of Errors
There are numerous sources of error in paired-end sequencing
strategies for rearrangement identification including experimental
artifacts, genome assembly errors or mis-mapping of end
sequences. These errors can lead to incorrect predictions of fusion
genes, or false positives. A major source of experimental artifacts in
current sequencing approaches is chimeric clones that are
produced when two non-contiguous regions of DNA are joined
together during the cloning procedure. Approximately 1–2% of
clones in modern BAC libraries are chimeric [21], and rates for
other vectors are roughly similar [15]. The type and rate of
experimental artifacts for new genome amplification and sequenc-
ing strategies is still an open question.
In order to assess the rate of false positive predictions of fusion
genes in the presence of errors, we simulated 100 random genome
rearrangements with 1% of the paired-end sequences arising from
chimeric clones. For several clone lengths, we recorded the
number of fusion genes correctly identified (true positives) and the
number of incorrect fusion gene predictions (false positives) as the
minimum fusion gene probability required for identification was
increased (Figure 8). For small numbers of paired reads, the largest
clones (150 kb) yield the largest number of true positives (Figure 8A
and 8B), while with a large number of paired reads, smaller clones
Figure 7. The number of paired reads necessary to detect fusion genes. (A) The number of paired reads necessary to detect fusion genes with
fusion probability greater than 0.5 as a function of gene size for different clone lengths. The vertical lines indicate median (20 kb) and mean (40 kb) sizes
for all known genes as well as the median (40 kb) and mean (90 kb) sizes for chimerDB genes. (B) The number of paired reads necessary to detect fusion
geneswithfusionprobabilitygreaterthan0.5asafunctionofclonelengthfordifferentfusiongenessizes(logscaleinbothaxes).Eachpointintheseplots
is the average over 100 different fusion genes and and 100 different simulations of clone sets from the genome. Thus, each data point represents the
average value of 10
4 simulations. In each simulation, a pair of genes was chosen such that area of the resulting gene rectangle (U6V) was equal to the
square of the indicated fusion gene size. A breakpoint was selected for the gene pair uniformly in the rectangle U6V).
doi:10.1371/journal.pcbi.1000051.g007
Figure6. Distribution ofgenesizes for differentgroupsofgenes.All genes: The ‘‘known genes’’ track in the UCSCGenome Browser [27]. Kinases:
Selectedfrom the KinBase database [36]. Transcription factors: Selected from the AmiGOdatabase accordingtothe GOterm‘‘transcriptionfactor activity’’
[37]. ChimerDB: Fusion genes in cancer extracted from the chimerDB database [23]. Random Fusion Genes: A set of 2000 genes involved in 1000 random
fusionevents.RandomFusioneventswereformedbyinducingrandombreakpoints,andselectingsucheventsiftheyformedafusiongene.Notethatthe
gene sizes are on a log scale, and the number of genes from each set used to derive each distribution is shown in the legend.
doi:10.1371/journal.pcbi.1000051.g006
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reads are required before very small clones (2 kb) become effective
(Figure 8D). On the other hand, these small clones show almost no
false positives at reasonable probability thresholds, and show little
(if any) increase in true positives if the probability threshold is
reduced (Figure 8D).
Finally, we examined the effect of chimeric clones on our ability
to identify breakpoints from invalid clusters. Obviously, when only a
single isolated invalid pair exists we cannot determine whether it
arose from a chimeric clone or from a true rearrangement.
However, a cluster of invalid pairs is highly unlikely to arise from
chimeric clones [20]. Figure 9 shows that in most cases, no clusters
of chimeric clones are observed. Even under high coverage (106
clonal coverage) and a very high percentage of chimeric clones
(5% of all paired reads) 80% of the time no chimeric clusters were
observed. This result demonstrates that clusters of two or more
invalid pairs are very likely to indicate true rearrangement events.
When comparing a fixed number of chimeric clones over clones of
varying lengths, the probability of observing a chimeric cluster is
much lower for smaller clones (Figure S8).
Discussion
We provided a computational framework to evaluate paired-end
sequencing strategies for detection of genome rearrangements in
cancer. Our probability calculations and simulations show that
current paired-end technology can obtain an extremely high
probability of breakpoint detection with a very low number of
reads. For example, more than 90% of all breakpoints can be
detected with paired-end sequencing of less than 100,000 clones
(Table 2). Additionally, next-generation sequencers can potentially
detect rearrangements with greater than 99% probability and
localizethebreakpoints ofthese rearrangementsto intervalslessthan
300 bp in a single run of the machine (Table 2). If only a fraction
(e.g. 50%) of the reads map uniquely, similar detection levels are
achievable by simply doubling the amount of sequencing.
We derived formulae that provide estimates of the probability of
detecting rearrangement breakpoints and localizing them precise-
ly. For a genome of length G with N mapped paired reads from
clones of length L, the detection probability is a function of the of
clonal coverage (c~ NL
G ). Thus, increasing L means that fewer
Figure 8. Sensitivity and specificity of fusion gene predictions. (A) Number of false positive (FP) and true positive (TP) fusion gene
predictions for a simulated genome with 100 translocations and 10,000 paired reads. Each curve represents the average of 50 simulations with clones
of a fixed length (2 kb, 40 kb, 150 kb clones). The minimum fusion probability threshold for indicating that a fusion gene was predicted was
decreased from ..95 (leftmost point) to .0 (rightmost point) in increments 0.05 and the number of true and false predictions was determined. For all
figures 19 true fusion genes were present in the rearranged genome. These 19 events were not selected for but rather they resulted from random
rearrangement of the genome. (B) 100,000 paired reads. (C) 1,000,000 paired reads. (D) 10,000,000 paired reads.
doi:10.1371/journal.pcbi.1000051.g008
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fusion. On the other hand, breakpoint localization depends
independently on ‘‘clone’’ length L, number of mapped reads N,
and genome size G. Traditionally, clone length L was dictated by
efficiency considerations with available cloning vectors (e.g.
plasmids<2 kb, fosmids<40 kb, and BACs<150 kb). However,
new sequencing technologies permit paired-end sequencing from a
larger range of ‘‘clone’’ lengths.
The natural question for the practitioner is: what sequencing
strategy maximizes information about rearrangements in the
cancer genome for minimum cost? Three considerations preclude
a definitive answer to the question. First, the goal of ‘‘maximizing
information about rearrangements’’ in cancer genomes requires
further specification. Second, the parameters of a sequencing
strategy cannot be set arbitrarily, but are restricted by the chosen
technology. Third, the complexity of cancer genomes at the
sequence level – including the number and type of rearrangements
and the sequence characteristics of rearrangement breakpoints – is
currently unknown We discuss each of these issues below and then
conclude by describing further extensions of our methodology.
Defining the Genomic Features of Interest
When studying genome rearrangements by paired-end sequenc-
ing approaches, there are two interrelated goals that affect the
choice of sequencing strategy. First, one might be interested in
detecting as many rearrangement breakpoints as possible with the
minimum amount of sequencing. In this case, the goal is to
maximize the clonal coverage c with the fewest number of paired
reads. It follows immediately from the breakpoint detection
probability (Equation 2) that for a fixed number of paired reads,
larger clones give higher probabilities of detection than smaller
clones. On the other hand, one might be interested in precise
localization of breakpoint regions. In this case, smaller clones
provide better localization when the breakpoint is detected
(Figure 8, Figure S5).
Better localization of breakpoints is desirable if one wants to
determine with certainty that a gene is fused or disrupted by a
genome rearrangement. Our results showed the correlation between
clone length and the probability of localizing breakpoints to an
interval of a specific length. Figure 5 shows that with a fixed number
of paired reads, the optimal choice of clone length depends on the
desired interval of localization. Figure 7B shows that these results
readilytranslatetotheprobabilityofdetectingfusiongenesofagiven
size. If paired-end sequences could be obtained for any clone length,
then the choice of optimal clone length depends on the length of
fusion genes that the researcher wants to have the greatest ability to
localize. This inturn might depend on a prior belief about the model
of rearrangement in cancer. For example, if one wants to be able to
localize fusion genes whose length is approximately the length of an
average human gene (40 kb), then the optimal clone length is 40 kb.
However, under the hypothesis that the breaks in the genome that
lead to fusion genes are distributed uniformly on the genome, larger
fusion genes would be expected and thus larger clones would be
optimal.
Better localization is also desirable when one wants to validate a
breakpoint via PCR, perhaps to determine if the breakpoint is
recurrent across multiple samples. In this case, the breakpoint
must be localized to an interval length that can be amplified via
PCR, typically less than a few kilobases, and thus smaller clones
are appropriate. On the other hand, in many cases rearrangement
breakpoints are known to vary across kilobases in different patients
[28]. Thus, approaches like Primer Approximation Multiplex
PCR (PAMP) [28] that assay for variable genomic lesions in a
patient population are useful, and the need for precise localization
of breakpoints is reduced. Nevertheless, the success of PAMP relies
on establishing reasonable boundaries of a rearrangement, so that
appropriate primers tiling the region can be designed [29]. Our
methodology provides these boundaries, and the combination of
paired-end sequencing and PAMP is a powerful tool for
identifying therapeutic targets and designing clinical diagnostics.
Choice of Sequencing Parameters
There are several next-generation sequencing technologies now
on the market, and others that soon will be commercially
available. Information about the capabilities of many of these
machines, particularly in regards to paired-end sequencing, is
presently limited. In addition, the field is developing rapidly and
any claims stated about read lengths, sequencing error rates, etc.
are undergoing continual revision. While our analysis focused on
several key parameters including number of paired reads, clone
length, and percent of chimeric clones, in reality only some of
these parameters are adjustable while others (e.g. error rate) are
fixed by the chosen sequencing technology.
One issue not considered in our model that is closely tied to the
sequencing technology is the mapping of reads to the reference
genome. Different sequencing technologies produce reads of
varying length and quality that can have a dramatic effect on
the ability to map paired reads. On one extreme, conventional
paired-end sequencing of cloned genomic fragments employed by
current ESP studies [9,21], yields high quality reads exceeding
500 bp. This enables the majority of reads outside of repeats and
segmental duplications to be uniquely and accurately mapped to
the reference genome. For example, with paired-end sequences
500 bp long, 11492 out of 19831 clones (58%) in the MCF7 study
mappeduniquely[22],while with paired-endsequences100 bplong
41% of paired reads using, mapped uniquely [15]. Newer
sequencing technologies such as Illumina and ABI have even
shorter reads (20 to 30 bp) and higher error rates [12,13], and the
ditag approach sequences only 18–20 base pairs from each end of
the genomic fragment [11]. These shorter reads will be much more
difficult to map, particularly when analyzing rearrangements.
Moreover, unlike resequencing studies, where one can increase
mapping efficiency using additional information that the end
sequences are close together on the reference genome, detection of
rearrangements specifically requires the accurate mapping of end
Figure 9. Probability of observing at least one chimeric cluster
vs. the percent of chimeric clones. These probabilities were
computed using Equation 27, with clone length L=150kb and
confirmed by simulation. Other clone lengths yield virtually identical
probabilities at the same clonal coverage. Note: the y-axis is log scaled.
doi:10.1371/journal.pcbi.1000051.g009
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informative to model the effect of different read accuracies and
lengths on the ability to accurately resolve breakpoints.
Organization of Cancer Genomes
Our simulations made certain simplifying assumptions about
the character of cancer genomes. Most notably, we assumed that
the size of the cancer genome (equal to the parameter G above) is
known. Since many cancer genomes, particularly solid tumors,
have extensive aneuploidy the actual size of a given genome might
differ greatly from normal cells [30]. At the present time, it is
difficult to calibrate the genome length parameter in our
simulations, and pilot sequencing studies will be needed to assess
the extent of amplification in these samples. Paired-end sequenc-
ing will naturally sample more from amplified regions. Although
we did not explicitly simulate amplifications, it is clear that the
probability of detecting amplified translocations is directly
proportional to their relative amplification in the genome.
Namely, as the number of copies, a, of a fusion point f increases,
the probability of detection Pf increases, approximately following
12e
2ca, assuming that the genome size is constant under the
amplification. Since highly amplified regions can have complex
organization due to duplication mechanisms [21,31], many of the
genome rearrangements detected in low coverage studies will likely
be in these highly amplified and rearranged regions. Identification
of non-amplified rearrangements might require extremely high
coverage.
An additional consideration is whether cancer rearrangement
breakpoints are biased to certain regions of the genome. For
example, if rearrangement breakpoints are in highly repetitive
regions, it might be difficult to map sequences that are too close to
the breakpoints, and thus larger clones are appropriate. On the
other hand, if there are multiple rearrangements clustered in a
small genomic interval as observed in the multiple breakpoints
found in some sequenced BACs and also in other recent
sequencing studies [22,32], larger clones would miss some of
these rearrangements. Finally, genomic heterogeneity, particularly
in primary tumor samples, reduces the effective coverage and thus
the probability of detecting rearrangement breakpoints. Even a
genomic lesion that is an important checkpoint in a cancer
progression, might be difficult to detect in an admixed sample
containing normal cells and cells from earlier developmental stages
of the tumor. It is nearly impossible to determine how all of these
factors will affect cancer sequencing strategies without further
studies. Such pilot studies promise to provide a significant increase
in new information about the extent of ploidy changes and
heterogeneity.
Extensions and Applications
Our formula for the probability of a fusion gene is readily
extended to fusions of other genomic features. For example, we
can compute the probability of regulatory fusions that result from
the fusion of the promoter of one gene to the coding region of
another gene. Other genomic assays such as array comparative
genomic hybridization (CGH) can be used in combination with
paired-end sequencing. Array CGH identifies breakpoints in-
volved in deletions and amplifications at average resolutions of less
than 10 kb [33,34]. If this information overlaps paired-end
sequencing data (such as the case with an amplified translocation
like BCAS4/BCAS3) it might be possible to improve the
resolution of the breakpoint interval defined by a paired-end
sequencing approach. As next-generation technologies mature and
the cost of sequencing declines, paired-end sequencing of cancer
genomes will inevitably provide highly reliable and precise
detection of fusion genes. Application of these technologies will
permit the systematic analysis of all classes of genomic events that
lead to cancer and will shed new light on the genetic and genomic
basis of cancer.
Methods
Mapping and Clustering of End Sequences
We assume that each clone C is end-sequenced and the ends are
mapped uniquely to the reference human genome sequence. Thus,
each clone C corresponds to a pair (xC,yC) of locations in the
human genome where the end sequences map. In addition, an end
sequence may map to either DNA strand, and so each mapped
end has a sign (+ or 2) indicating the mapped strand. We call such
a signed pair an end sequence pair (ES pair). In general the length
(insert size) LC of the clone C is unknown, but is restricted to be in a
range [Lmin,Lmax]. For most clones the observed distance between
mapped ends will lie within this range and the ends will have
opposite, convergent orientations: i.e. the corresponding ES pair
will have the form (+x,2(x+LC)). Following [20] we call such ES
pairs valid pairs because these indicate no rearrangement in the
cancer genome. We use the distribution of distance |y|2|x|
between the ends of valid pairs to define an empirical distribution
of clone lengths (cf. Figure S1).
If a pair (xC,yC) has ends with non-convergent orientation or
whose distance |y|2|x| is greater than Lmax or smaller than Lmin,
we say that (xC,yC)i sa ninvalid pair. The set of breakpoints (a,b) that
are consistent with the invalid pair (xC,yC) is determined by the
inequalities [35]
Lminƒ sign xC ðÞ a{xC ðÞ zsign yC ðÞ b{yC ðÞ ƒLmax: ð6Þ
Throughout the paper, we assume (without loss of generality) that
sign(xC)=sign(yC)=+ so that a$xC and b$yC.
Validating Fusion Predictions by Sequencing
Clones containing predicted fusion genes were draft sequenced
(16 coverage) by subcloning into 3 kb plasmids as described in
[22]. Assembly of these sequences and alignment to the reference
human genome identified either the precise fusion point, or
identified a plasmid containing the fusion point thereby localizing
the breakpoint to 3 kb.
Computing Fusion Probability
Define C(a,b) as the event that a clone C from the cancer genome
with corresponding invalid pair (xC,yC) overlaps a breakpoint (a,b)
of a reference genome. Assume w.l.o.g. that the invalid pair (xC,yC)
is oriented such that a$xC and b$yC. The length LC of the clone is
then equal to
lC a,b ðÞ ~ a{xC ðÞ z b{yC ðÞ ~ azb ðÞ { xCzyC ðÞ : ð7Þ
Thus, the event C(a,b) implies the event LC=lC(a,b), allowing us to
express the probability of occurrence of breakpoint (a,b) in terms of
the distribution on the lengths of clones. Let NC[s] denote the
number of discrete breakpoints (a,b) such that a$xC, b$yC, and
a+b=s. Then
Pr C a,b ðÞ
  
~Pr C a,b ðÞ \ LC~lC a,b ðÞ ðÞ
  
ð8Þ
~Pr C a,b ðÞ LC~lC a,b ðÞ j
   :Pr LC~lC a,b ðÞ ðÞ ð 9Þ
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1
NC lC azb ðÞ ½ 
Pr LC~lC a,b ðÞ ðÞ , ð10Þ
where the last equality follows from Equation 7 and the
assumption that all breakpoints are equally likely.
Now consider a pair of genes spanning genomic intervals U and
V. An in-frame fusion transcript is possible if and only if exactly one
of the genes is on the ‘‘+’’ strand and the other is on the ‘‘2’’
strand. In this case, the probability of a fusion gene being formed
between these two genes given a clone C is the probability that the
breakpoint (a,b)i nC is also in U6V. This probability is
Pr | a,b ðÞ [U|VC a,b ðÞ
  
~
X
a,b ðÞ [U|V
Pr LC~lC a,b ðÞ ðÞ
NC azb ½ 
: ð11Þ
Otherwise, if the genes are both on the same strand then an in-
frame fusion transcript is impossible, and we define the fusion
probability to equal zero. A similar analysis yields fusion gene
probabilities in the cases of invalid pairs with other signs, by
considering pairs of genes with compatible orientations. In the
simple case, we assume that the clone lengths are uniformly
distributed over the range [Lmin,Lmax], so that
Pr LC~lC a,b ðÞ ðÞ ~
1
Lmax{Lmin
if LminƒlC a,b ðÞ ƒLmax
0 otherwise
8
<
:
In this case, Equation 11 gives the fraction of the trapezoid
(Equation 1) that intersects U6V. A more accurate distribution of
clone lengths is obtained from the empirical distribution of
distance between ends of valid ES pairs (Figure S1), and this
distribution can also used to compute Pr(LC=lC(a,b)).
Next, we extend the equations to include the case when a set
{C
(1),C
(2),…} of multiple clones overlap the breakpoint (a,b). Define
C to be the event that all clones overlap the same breakpoint. Then
C~| a,b ðÞ C a,b ðÞ
where
C a,b ðÞ ~\jC
j ðÞ
a,b ðÞ
is the event that all clones C
(j) overlap the breakpoint (a,b). Thus,
the probability of (a,b) being the breakpoint given that all clones
overlap it is given by
Pr C a,b ðÞ C j
  
~
Pr C a,b ðÞ \C
  
Pr C ðÞ
ð12Þ
~
Pr C a,b ðÞ
  
Pr C ðÞ
ð13Þ
~
P
j
Pr C
j ðÞ
a,b ðÞ
  
P
a,b ðÞ
P
j
Pr C
j ðÞ
a,b ðÞ
  ð14Þ
Here, Equation 13 follows from the fact that C(a,b) implies C, and
Equation 14 follows from the independence of clones. This allows
us to compute the probability that the genes spanning genomic
intervals U and V fuse by
Pr | a,b ðÞ [U|VC a,b ðÞ C j
  
~
P
a,b ðÞ [U|V
P
j
Pr C
j ðÞ
a,b ðÞ
  
P
a,b ðÞ
P
j
Pr C
j ðÞ
a,b ðÞ
   : ð15Þ
Algorithms for Efficient Probability Computation
The naive approach for computing Pr(<(a,b)MU6VC(a,b)|C)i n
Equation 15 is to compute Pr C
j ðÞ
a,b ðÞ
  
over all (a,b) and all clones
C
(j), which is time consuming. We exploit several features of this
equation to make the computation more efficient. First, it is not
necessary to compute Pr C
j ðÞ
a,b ðÞ
  
over all (a,b)i nU6V, but only
those (a,b) contained in the intersection of all of the trapezoids
defined by the clones. Second, Equation 10 implies that
lC a,b ðÞ ~lC a0,b0 ðÞ [Pr C
j ðÞ
a,b ðÞ
  
~Pr C
j ðÞ
a’,b’ ðÞ
  
Finally, since lc(a,b)=(a+b)2(xC2yC) the points (a,b) with equal
values of lC(a,b) lie on a line with slope 21 (an antidiagonal). This
provides a methodology for rapidly computing the probability of
fusion.
For an integer s, define the diagonal Ds as the set of integral points
(a,b) on the line a+b=s that are overlapped by all clones. Thus,
Ds~ a,b ðÞ : a§xC j ðÞand b§yC j ðÞVj, azb ðÞ ~s fg :
Hence, D=<sDs is the set of breakpoints that are overlapped by
all clones. Define the diagonal probability as a product of the
probabilities of these clone lengths
Ps~P
j
Pr C j ðÞ        ~ s{xC j ðÞ{yC j ðÞ ðÞ
  
NC j ðÞs ½ 
Then, we have
Pr | a,b ðÞ [U|VC a,b ðÞ C j
  
~
P
a,b ðÞ [U|V\D
P
j
Pr C
j ðÞ
a,b ðÞ
  
P
a,b ðÞ [D
P
j
Pr C
j ðÞ
a,b ðÞ
  
~
P
s
P
a,b ðÞ [U|V\Ds
P
j
Pr C
j ðÞ
a,b ðÞ
  
P
s
P
a,b ðÞ [Ds
P
j
Pr C
j ðÞ
a,b ðÞ
  
~
P
s
Ds\U|V jj :Ps
P
s
Ds jj :Ps
Thus we compute |Ds|, |Ds>U6V|, Ps, for all values of s
intersected by all clones. This is more efficient than Equation 15,
since there are relatively few diagonals with Ps.0 and |Ds|.0.
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We now compute the probability of detecting a fusion point and
the expected number of fusion points that are detected as a
function of the number and length of clones that are end-
sequenced. Recall that a breakpoint (a,b) is defined as a pair of non-
adjacent coordinates a and b in the reference genome that are
adjacent in the cancer genome, and a fusion point is defined as the
coordinate f in the cancer genome such that a maps to f and b
maps to f+1. Assume that N clones, each of length L, are end
sequenced from a cancer genome of size G. We assume that the left
endpoint of each clone is selected uniformly at random from the
cancer genome. Then a fusion point f is detected if a clone
contains it. Thus, the probability Pf of detection is given by [25,26]
Pj~1{ 1{
L
G
   N
&1{e{NL
G ~1{e{c, ð16Þ
where c~ NL
G is the clonal coverage. Suppose there are M fusion
points in the cancer genome, and define the random variables
X1,…,XM by Xi=1 if the i-th fusion point is covered and Xi=0,
otherwise. Then
EX i ðÞ ~1{e{c:
The expected number of fusion points detected is given by
EX ðÞ ~
X M
i~1
EX i ðÞ ~M 1{e{c ðÞ :
Using the Poisson approximation with l=M(12e
2c)
Pr m fusion points detected ½  &
e{ll
m
m!
:
Given m observed fusion points, the maximum likelihood estimator
M ˆ of the total number of fusion points is
^ M M~
m
1{e{c : ð17Þ
Localization of Fusion Points
If one or more clones contain a fusion point f, the localization of f
is defined as the length of the shortest interval that contains f
according to the mapped locations of the clone ends. The
localization is generally improved (i.e. decreased) when more
clones contain a fusion point. Define Hf as the intersection of all
clones that cover f (Figure 4). We compute the probability
distribution on the length of Hf as follows. Following Lander-
Waterman [26], we assume that the left endpoints of clones follow
a Poisson process with intensity c~ NL
G on the interval G. Hf is
determined by the left endpoint of the right-most clone that
contains f and the right endpoint of the left-most clone that
contains f. Define for 0#j#L21 as the event in which the right-
most clone has its left endpoint j nucleotides to the left of f.
Correspondingly, define Bj,1 #j#L as the event that the left-most
clone has its right endpoint j nucleotides to the right of f. The
event Aj occurs when there is a clone with left endpoint at f2j and
no clones with left endpoints in the interval j nucleotides to the
right of f2j, and similarly for Bj. Therefore,
Pr Aj
  
~Pr Bj
  
~e{
jN
G 1{e{N
G
  
: ð18Þ
The events are mutually exclusive for all j, and likewise for . Thus,
we can express Pf as
Pj~Pr |L{1
j~0 Aj
  
~ 1{e{N
G
   X L{1
j~0
e{
jN
G
~ 1{e{NL
G
  
~1{e{c:
ð19Þ
Note that if s,L, then As2j and Bj are independent for all j.T o
compute the probability distribution on |Hf|, we have two cases.
For s,L,
Pr Hj jj ~s ðÞ ~Pr |s
j~0 As{j\Bj
     
~
X s
j~0
Pr As{j\Bj
  
~
X s
j~0
Pr As{j
  
Pr Bj
  
~se{sN
G 1{e{N
G
   2
ð20Þ
The event |Hf|=L requires all clones covering f to have the same
left endpoint. Therefore
Pr Hj jj ~L ðÞ ~Le{c 1{e{N
G
  
ð21Þ
We can compute the expected length of Hf conditioned on f being
covered by a clone; otherwise Hf is undefined. Since the event
|Hf|#L occurs only when f is covered, we have
Pr Hj jj ~s j is covered j ðÞ ~
Pr Hj jj ~s ðÞ
Pr j is covered ðÞ
~
Pr Hj jj ~s ðÞ
1{e{c :ð22Þ
Combining 20, 21, and 22 obtains
E Hj jj j is covered j ðÞ ~
1{e{N
G
1{e{c
 !
| L2e{cz
X L{1
s~0
s2e{Ns
G 1{e{N
G
  
 !
:
ð23Þ
We note that the sum in the above formula has a closed form
solution:
E Hj jj j is covered j ðÞ ~
1{e{N
G
1{e{c
 !
L2e{c{
1
1{e{N
G
   2
2
6 4
e{N
G 1ze{N
G
  
{ec L2 1{e{N
G
  
z L{1 ðÞ
2e{N
G 1ze{N
G
        
3
7 5
ð24Þ
Because of the presence of chimeric clones, it is be useful to
consider a fusion point f to be detected if is it covered by a cluster of
2 or more invalid pairs. In this case,
Pj&1{e{c{
NL
G
e
N{1 ðÞ L
G , ð25Þ
Evaluation of Cancer Sequencing Strategies
PLoS Computational Biology | www.ploscompbiol.org 12 April 2008 | Volume 4 | Issue 4 | e1000051and
E Hj jj j is covered by multiple clones j ðÞ
~
1{e{N
G
1{ e{cz NL
G e{
N{1 ðÞ L
G
  
0
@
1
A
|
X L{1
s~0
s2e{Ns
G 1{e{ÞFN ,G ðÞ
  
 !
:
ð26Þ
It is also useful to compute the probability that two or more
chimeric clones form a cluster. Let N be the total number of paired
reads as defined above and q be the probability that a mapped
clone is chimeric. If we assume that the distribution of clone
lengths has mean L and is uniformly distributed in the interval
[Lmin,Lmax], then
P at least one pair of chimeric clones overlap ðÞ
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Supporting Information
Text S1 Supporting Methods.
Found at: doi:10.1371/journal.pcbi.1000051.s001 (0.05 MB PDF)
Figure S1 Distribution of MCF7 clone lengths. The mean for this
distribution is 122 kb, and the standard deviation is 24 kb. Fusion
Probabilities in Table 1 are computed using this distribution and the
putative fusion regions for each gene pair (see Methods).
Found at: doi:10.1371/journal.pcbi.1000051.s002 (0.03 MB PDF)
Figure S2 Length of a breakpoint region (BPR) for varying
amounts of clonal coverage. The blue curve shows the expected
length (Equation 5), while the red curve is the average observed
length over 50 simulations.
Found at: doi:10.1371/journal.pcbi.1000051.s003 (0.03 MB PDF)
Figure S3 Clone length vs. Pf vs. |Hf| for varying N. A clear
trade-off can be observed. Larger clone lengths yield higher Pf
(detection probability), compared to smaller clone lengths, which
have the advantage of better localization (smaller |Hf|). Different
lines originating from 0 refer to different number of reads. As the
number of reads grows, the trade-off converges to high detection,
and better localization. (A) shows values in a mesh graph, while (B)
shows raw values.
Found at: doi:10.1371/journal.pcbi.1000051.s004 (0.45 MB PDF)
Figure S4 The effect of clone length and number of paired reads
on Pf and |Hf|. (A) Pf increases as the number of paired reads N
or clone length L increases, but is constant as a function of N/L. (B)
|Hf| decreases as the number of paired reads increases or the
clones length decreases. Note that all axes are log values (with the
exception of Pf in [A]).
Found at: doi:10.1371/journal.pcbi.1000051.s005 (0.42 MB PDF)
Figure S5 Pf and |Hf| for different L and N. (A) The probability
of detecting a fusion point, Pf, for different clone lengths and
varying number of mapped paired reads. (B) The expected length
of a breakpoint region, |Hf|, around a fusion point (assuming that
the fusion point is contained in a clone).
Found at: doi:10.1371/journal.pcbi.1000051.s006 (0.18 MB PDF)
Figure S6 The number of paired-reads (and resulting E(|Hf|))
needed to obtain a Pf of 0.99 for clone lengths varying from 1 to
150 kb. The x-axis indicates clone length, L, the y-axis indicates
reads, N, and the alternate y-axis shows |Hf|. The vertical line
indicates the intersection point between the two lines at
,16,000 bp.
Found at: doi:10.1371/journal.pcbi.1000051.s007 (0.33 MB PDF)
Figure S7 Average fusion probability vs. number of mapped
reads. The average fusion probability with mean and standard
deviations as a function of N, the number of mapped paired reads.
The x-axis represents the number of clones sequenced, N. The
simulated fusion genes were 200 kb.
Found at: doi:10.1371/journal.pcbi.1000051.s008 (0.06 MB PDF)
Figure S8 Effect of chimeric clones. The probability of
observing at least one chimeric cluster for a fixed number of
paired reads as a function of the percent of chimeric clones
indicates that the observed rate of chimerism is lower for smaller
clones. (A) 1 kb clones, (B) 10 kb clones, (C) 40 kb clones, and (D)
150 kb clones.
Found at: doi:10.1371/journal.pcbi.1000051.s009 (0.05 MB PDF)
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